HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: IND Applications For Cosmetic Trials? Lauder Appointment; P&G At Olympics

This article was originally published in The Rose Sheet

Executive Summary

Comments may be submitted through April 7 regarding cosmetics-related sections in an FDA guidance that could impose the costs and burden of Investigational New Drug application on beauty companies conducting clinical trials. More news in brief.

You may also be interested in...



Unilever Looks To Personal-Care Innovation, Improved “Agility” In FY 2014

Unilever reports a 3% decline in FY 2013 turnover, but underlying sales growth was ahead of market, the firm says, crediting strong innovation in personal care and successes in emerging markets, among other factors. Going forward the firm aims to create efficiencies via SKU reductions and other streamlining efforts.

FDA Guidance Could Impose Drug-Like Burden On Cosmetic Trials

An FDA guidance document intended to clarify if firms conducting certain drug studies involving human subjects are obligated to file Investigational New Drug Applications instead raises questions for the cosmetics industry.

EMA Set To Discuss Safety Of Ranitidine Drugs Soon

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

Related Companies

UsernamePublicRestriction

Register

RS019350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel